Global Lung Cancer Screening Software Market, By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributors) – Industry Trends and Forecast to 2031.
Lung Cancer Screening Software Market Analysis and Size
The global lung cancer screening software market is majorly used in treatment, planning and monitoring of lung cancer. The software plays a crucial role in facilitating efficient and personalized treatment strategies for lung cancer patients by assisting healthcare professionals in analyzing diagnostic data, tracking disease progression, and tailoring treatment plans. It aids in monitoring the effectiveness of interventions, enabling timely adjustments for improved patient outcomes.
Data Bridge Market Research analyses the global lung cancer screening software market, which was USD 39,698.69 thousand in 2023, is expected to reach USD 1,63,987.52 thousand by 2031, at a CAGR of 19.40% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributors)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Koninklijke Philips N.V (Netherlands), Volpara Health Limited (New Zealand), Thynk Health (U.S.), Siemens Healthcare GmbH (Germany), Magview (U.S.), MeVis Medical Solutions AG (Germany), CANON MEDICAL SYSTEMS EUROPE B.V. (U.S.), HealthCare. GE (U.S.), Epic Systems Corporation (U.S.), Lungview (U.S.), Eon (U.S.), Medtronic (Ireland), core:line Inc (South Korea), Optellum Ltd (U.K.), Oncocyte Corporation (U.S.), Genesystem (South Korea), REVEALDX (U.S.), FUJIFILM Holdings Corporation (Japan), F. HoffmannLa Roche Ltd (Switzerland), Median Technologies (France), AstraZeneca (U.K.), Aidence (Netherlands)
|
|
Market Opportunities
|
|
Market Definition
Lung cancer screening software refers to specialized computer programs designed to assist in the early detection of lung cancer through the analysis of medical imaging, such as CT scans. These applications utilize advanced algorithms to identify and analyze potential abnormalities, helping radiologists and healthcare professionals to detect suspicious nodules or lesions in the lungs at an early stage. Early detection can significantly improve the chances of successful treatment and better patient outcomes.
Global Lung Cancer Screening Software Market Dynamics
Drivers
- Rising Lung Cancer Incidence Fuels the Demand for Effective Treatment Options
As the prevalence of lung cancer continues to rise, there is an increasing need for advanced and effective treatment options. Lung cancer screening software plays a crucial role in early detection, aiding healthcare professionals in identifying and treating the disease at its nascent stages. The growing awareness about the significance of early intervention is prompting healthcare providers to
- Enhanced Lung Cancer Screening Efficiency through Technological Imaging Advancements
As medical imaging technologies such as computed tomography (CT) and positron emission tomography (PET) continue to evolve, they enable more precise and detailed lung cancer screening. The global lung cancer screening software market is propelled by the demand for sophisticated software solutions capable of efficiently handling and analyzing the increasingly complex imaging data. These advancements contribute to improved diagnostic accuracy, and better patient outcomes.
Opportunities
- Rising Trend of Telemedicine in Remote Areas
Lung cancer screening software can extend its reach to remote by leveraging telemedicine platforms, and underserved populations, enhancing accessibility and increasing the adoption of screening programs. This trend allows for seamless integration of screening software with virtual consultations, facilitating timely communication between healthcare providers and patients.
- Enhanced Diagnostics Through Integration with Multimodal Imaging
The integration of global lung cancer screening software with multimodal imaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), offers a pivotal opportunity for enhanced diagnostics. These software solutions enable a more comprehensive by combining data from diverse imaging source and detailed analysis of lung abnormalities. This integration facilitates a holistic approach to lung cancer screening, providing healthcare professionals with a more nuanced understanding of the disease.
Restraints/Challenges
- Challenges Arising From Regulatory Evolution Result In Delays For Product Launches
The stringent and continually evolving regulations pertaining to healthcare software, particularly in the context of lung cancer screening, pose hurdles for companies seeking market entry. Compliance with these regulations demands thorough testing, validation, and approval processes, contributing to extended timelines for product development and launch. As a result, companies operating in the market may experience delays in introducing their screening software, impacting the growth and pace of innovation in the global lung cancer screening software market.
- High Implementation Costs Limits Technology Adoption in Hospitals
The substantial financial investment required for integrating advanced screening software into existing healthcare systems can deter hospitals and healthcare providers, particularly in regions with constrained budgets. This financial barrier hampers the seamless incorporation of innovative lung cancer screening solutions, hindering the market's potential growth.
This global lung cancer screening software market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global lung cancer screening software market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In November 2023, Aidence, Incepto, and Thirona collaboratly launched a clinical solution aimed at supporting the expansion of lung cancer screening in Europe. This collaborative effort signifies a strategic move to enhance screening capabilities and contribute to advancements in detecting and managing lung cancer across the continent
- In July 2022, GE Healthcare strengthened its position in the healthcare sector by launching the Voluson Expert 22, the most advanced ultrasound in its Women’s Health portfolio. Utilizing graphic-based beam former technology, this product offers superior imaging quality and enhanced flexibility, reinforcing GE Healthcare's commitment to providing cutting-edge products and services to healthcare institutions
- In October 2021, Thynk Health announced a strategic collaboration with Infervision, leveraging the world's most advanced technologies to combat lung cancer. This collaboration not only facilitates advanced lung cancer screening but also strengthens Thynk Health's market presence, positioning the company as a key player in pulmonary nodule management and innovative healthcare solutions
Global Lung Cancer Screening Software Market Scope
The global lung cancer screening software market is segmented into eight notable segments based on mode of delivery, product, type, application, platform, purchase mode, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Mode of Delivery
- Cloud Based Solutions
- On-Premise Solutions
- Web Based Solutions
Product
- Lung Cancer Screening Radiology Solution
- Lung Cancer Screening Patient Management Software
- Nodule Management Software
- Data Collection and Reporting
- Patient Coordination and Workflow
- Lung Nodule Computer Aided Detection
- Pathology and Cancer Staging
- Statistical Audit Reporting
- Screening PACS
- Practice Management
- Audit Log Tracking
Type
- Computer-Assisted Screening
- Traditional Screening
Application
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
Platform
- Standalone
- Integrated
Purchase Mode
- Institutional
- Individual
End User
- Oncology Centers
- Hospitals
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Direct Tender
- Third Party Distributors
Global Lung Cancer Screening Software Market Regional Analysis/Insights
The global lung cancer screening software market is analyzed and market size insights and trends are provided based on mode of delivery, product, type, application, platform, purchase mode, end user and distribution channel as referenced above.
The countries covered in the global lung cancer screening software market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, U.A.E., Saudi Arabia, Israel, Egypt, South Africa, and rest of Middle East and Africa.
The North America is expected to dominate the market and experience rapid growth, driven by several key factors. This includes the surge in screening programs, a rising adoption of software solutions for effective patient management, an increased demand for screening utilizing chest radiography, and the substantial presence of numerous screening centers. These combined elements underscore North America's dominance in the lung cancer screening software market, emphasizing its pivotal role in shaping the industry landscape.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global lung cancer screening software market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global lung cancer screening software market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global lung cancer screening software market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Lung Cancer Screening Software Market Share Analysis
The global lung cancer screening software market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global lung cancer screening software market.
Some of the major players operating in the global lung cancer screening software market are:
- Koninklijke Philips N.V (Netherlands)
- Volpara Health Limited (New Zealand)
- Thynk Health (U.S.)
- Siemens Healthcare GmbH (Germany)
- Magview (U.S.)
- MeVis Medical Solutions AG (Germany)
- CANON MEDICAL SYSTEMS EUROPE B.V. (U.S.)
- HealthCare. GE (U.S.)
- Epic Systems Corporation (U.S.)
- Lungview (U.S.)
- Eon (U.S.)
- Medtronic (Ireland)
- core:line Inc (South Korea)
- Optellum Ltd (U.K.)
- Oncocyte Corporation (U.S.)
- Genesystem (South Korea)
- REVEALDX (U.S.)
- FUJIFILM Holdings Corporation (Japan)
- F. HoffmannLa Roche Ltd (Switzerland)
- Median Technologies (France)
- AstraZeneca (U.K.)
- Aidence (Netherlands)
SKU-